key: cord-0717355-5i0m18nt authors: Kuzumi, A.; Yoshizaki, A.; Chiba, K.; Mitsuo, S.; Matsuda, K.M.; Norimatsu, Y.; Nagai, K.; Omatsu, J.; Miyake, T.; Sato, S. title: Genital necrosis with cutaneous thrombosis after COVID‐19 mRNA vaccination date: 2021-12-10 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17837 sha: cc578e4f6bf74aa7fe1e084397fef3ae6bb06c4e doc_id: 717355 cord_uid: 5i0m18nt Thrombosis is a rare complication of COVID-19 vaccines that typically affects cerebral and visceral vessels. However, skin involvement is largely unknown.5,6 Here, we describe a case of genital necrosis associated with cutaneous thrombosis following COVID-19 vaccination. neutrophils and lymphocytes in the dermis, and thrombotic occlusion of dermal vessels with mild perivascular infiltration (Fig. 1b,c) . Immunohistochemistry revealed that the thrombi were positive for CD61, a platelet-specific marker (Fig. 1d,e) . Based on the clinical and histopathological findings, a diagnosis of cutaneous necrosis with platelet thrombi formation and secondary infection was made. Treatment was started with ampicillin/sulbactam along with local wound care. Her fever, leukocytosis and genital pain resolved within the first week. The skin lesions also improved: more than 80% of the eschar had fallen off when she was discharged after one month of admission (Fig. 2a) , and epithelization was almost completed another month later (Fig. 2b) . A small but increasing number of thrombotic events have been reported since the launch of mass vaccination campaigns against COVID-19. Adenovirus vector-based vaccines from AstraZeneca (Cambridge, UK) and Johnson & Johnson (Titusville, NJ, USA) are associated with severe thrombosis with thrombocytopenia, while mRNA-based vaccines from Pfizer-BioNTech and Moderna (Cambridge, MA, USA) are also associated with some thrombotic events, which do not always accompany thrombocytopenia. [1] [2] [3] [4] The exact pathogenesis remains unknown, but platelet activation is thought to be a key feature underlying these events. 7 For both types of vaccines, thrombosis typically occurs in unusual locations such as cerebral and portal veins. However, only two cases of skin involvement have been reported, both of which manifested as local skin necrosis at injection sites. 5, 6 To the best of our knowledge, this is the first case of extensive skin necrosis after COVID-19 vaccination that developed outside the injection site. Although the mechanism of platelet thrombi formation in genital skin is unclear, the short time interval between the vaccination and the onset of symptoms may indicate a causal relationship. Therefore, our case extends the range of cutaneous manifestations associated with thrombosis after COVID-19 vaccination. In addition, it should be noted that she developed thrombosis despite receiving edoxaban, which highlights the need to consider the possibility of thrombosis even in patients under anticoagulant therapy. Although rare, skin necrosis should be recognized as a possible manifestation of thrombosis associated with COVID-19 vaccination. Dear Editor, During the Coronavirus disease 2019 (COVID-19) pandemic, dermatologists are dealing with challenging clinical scenarios in their clinical practice. A wide range of cutaneous manifestations has been described, either directly associated with the COVID-19, or as a consequence of management procedures, as well as an exacerbation of previous cutaneous conditions. 1 We have read with great interest the paper published by Barrera-Godinez et al., 2 in which they mention Pityrosporum folliculitis in COVID-19 patients. We have recently evaluated three patients in the intensive care unit (ICU), diagnosed with COVID-19 acute respiratory distress syndrome (ARDS) presenting similar cutaneous manifestations. Initially, we were called to evaluate a 52-year-old obese man, with type 2 diabetes, under mechanical ventilation in a prone position and receiving systemic corticosteroids, due to a severe COVID-19 ARDS. He had also evolved with acute renal failure and septic complications (ventilator-associated pneumonia and septic shock by bloodstream infection), using several systemic antibiotics. A monomorphic eruption of follicular erythematous papules and pustules was observed on the chest, upper and lower limbs, on the back and abdomen after 6 days in the ICU. We Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: a black swan event Central venous sinus thrombosis with subarachnoid hemorrhage following an mRNA COVID-19 vaccination: are these reports merely co-incidental? Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination Skin necrosis at both COVID-19 vaccine injection sites Autoimmunity roots of the thrombotic events after COVID-19 vaccination Pityrosporum folliculitis in critically ill COVID-19 patients